Gross Profit Margin (Quarterly) Chart

View Gross Profit Margin (Quarterly) for ADDLF.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Gross Profit Margin (Quarterly) Chart
Start Trial

Historical Gross Profit Margin (Quarterly) Data

View and export this data back to 2014. Start Trial.
Date Value
March 31, 2026 38.68%
December 31, 2025 38.09%
September 30, 2025 37.38%
June 30, 2025 38.94%
March 31, 2025 37.90%
December 31, 2024 37.05%
September 30, 2024 37.29%
June 30, 2024 38.10%
March 31, 2024 37.67%
December 31, 2023 36.16%
September 30, 2023 37.04%
June 30, 2023 37.84%
March 31, 2023 37.69%
December 31, 2022 37.15%
September 30, 2022 35.76%
June 30, 2022 39.01%
March 31, 2022 38.81%
December 31, 2021 36.60%
September 30, 2021 35.68%
June 30, 2021 37.21%
March 31, 2021 35.89%
December 31, 2020 35.07%
Date Value
September 30, 2020 34.65%
June 30, 2020 33.01%
March 31, 2020 35.04%
December 31, 2019 34.31%
September 30, 2019 34.91%
June 30, 2019 34.48%
March 31, 2019 34.08%
December 31, 2018 35.77%
September 30, 2018 34.95%
June 30, 2018 36.50%
March 31, 2018 36.18%
December 31, 2017 36.68%
September 30, 2017 35.01%
June 30, 2017 36.71%
March 31, 2017 35.59%
December 31, 2016 34.24%
September 30, 2016 33.51%
June 30, 2016 35.25%
March 31, 2016 35.26%
March 31, 2015 35.72%
December 31, 2014 37.20%

Gross Profit Margin Definition

Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.

Read full definition.

Gross Profit Margin (Quarterly) Range, Past 5 Years

View Gross Profit Margin (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Gross Profit Margin (Quarterly) Benchmarks

View Gross Profit Margin (Quarterly) Benchmarks
Start Trial
Arjo AB 39.21%
Henry Schein, Inc. 29.78%
Accendra Health, Inc. 39.05%
Fuse Medical, Inc. --
CeCors, Inc. --